<DOC>
	<DOC>NCT00545142</DOC>
	<brief_summary>To demonstrate the efficacy and safety of co-administration of Abilify(aripiprazole) with Depakote(divalproate) in the acute phase of 6-week treatment of acute mania in patients with bipolar disorder.</brief_summary>
	<brief_title>Abilify in Bipolar Disorder for 6 Weeks Treatment Effectiveness</brief_title>
	<detailed_description>Further study details as provided by Korea OIAA</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Valproic Acid</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<criteria>1. Mania or mixed episode of Bipolar disorder Bipolar disorder, mania or mixed episode according to DSMIV 2. The periods of mania or mixed episode should be within 3 months, and YMRS score at enrollment be more than 20. 3. Male and female between the age of 18 and 65 (In case of childbearing women, negative pregnancy test results should be confirmed before the administration of the investigational drug and appropriate contraception be used. Pregnant and breastfeeding women cannot be included) 4. Patients who can consent to participate in this clinical trial 5. Patients who understand this trial and comply with all protocol requirements 1. Patients with the following clinical symptoms diagnosed using DSMIV: Delirium, dementia, amnestic or other cognitive disorders Schizophrenia or schizoaffective disorder 2. Patients who do not respond to clozapine 3. Patients who are expected to require the administration of prohibited concomitant drugs during the clinical trial period 4. Patients diagnosed with substancerelated disorder according to DSMIV within the past 3 months (abuse, intoxication, dependency and/or withdrawal symptoms). The abuse of benzodiazepines is included with the exception of caffeine or nicotine. 5. Patients known to have allergy or hypersensitivity reaction to Ablify(aripiprazole) or other quinolinones 6. Patients at high risk of suicide attempt or with the history of murder or mental status test 7. Patients with the history of neuroleptic malignant syndrome 8. Patients with the past history which may cause serious adverse events that can affect the safety or efficacy evaluation during the clinical trial period 9. Patients with vital sign or ECG results in the clinically significant abnormal laboratory test Patients with clinically significantly abnormal laboratory results, vital sign or ECG results 10. Pregnant women or childbearing women who do not or cannot use appropriate contraception 11. Patients given psychotropic medications (except benzodiazepines) one day before baseline visit 12. Patients treated with Fluoxetine for the last 4 weeks 13. Patients who participated in clinical trials with other investigational drugs for the last one month 14. Patients with the history of convulsive disorder 15. Patients with the history of more than 4 mood episodes each year (rapid cycling) during the last 2 years prior to screening.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2010</verification_date>
</DOC>